Lipitor sales take a nosedive; Pfizer stock follows

Categories: Prescription Drugs

Pfizer took a pounding in the stock market today after announcing poor earnings. The drug giant blamed increased competition from generics and lower than anticipated earnings from Lipitor, it’s bread-and-butter brand. According to Reuters,

The world’s biggest drug maker, whose shares fell more than 3 percent in morning trading, said it earned $1.27 billion, or 18 cents per share in the second quarter. That compares with $2.42 billion, or 33 cents per share, a year earlier…

“I think this is a disappointing result, particularly relative to their first-quarter report,” Leerink Swann & Co. analyst Seamus Fernandez said.

Yep, I think I’d be disappointed.

About Cary Byrd

eDrugSearch founder, Cary Byrd, has been called an “e-health innovator” by MarketIntellNow, interviewed by top pharmaceutical industry journalists, invited to Matthew Holt’s Health 2.0 Conference and a Consumer Report's health summit, and highlighted on numerous health blogs.

eDrugSearch.com - Search. Compare. Save.

Leave a Reply

Join Our Free Newsletter

Please enter email id

Get a weekly dose of money-saving tips on your medications, drug side effects alerts, drug interaction warnings, free prescription coupons, late-breaking safety information and much, much more!

Share via
Copy link